[1]闫　欣,商素亮,李　娜,等.血浆S1P和HDL-C表达水平与帕金森病患者临床症状的相关性研究[J].现代检验医学杂志,2022,37(03):182-186.[doi:10.3969/j.issn.1671-7414.2022.03.038]
　YAN Xin,SHANG Su-liang,LI Na,et al.Correlation between Plasma S1P, HDL-C Expressions Levels and Clinical Symptoms in Patients with Parkinson’s Disease[J].Journal of Modern Laboratory Medicine,2022,37(03):182-186.[doi:10.3969/j.issn.1671-7414.2022.03.038]
点击复制

血浆S1P和HDL-C表达水平与帕金森病患者临床症状的相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年03期
页码:
182-186
栏目:
检验与临床
出版日期:
2022-05-15

文章信息/Info

Title:
Correlation between Plasma S1P, HDL-C Expressions Levels and Clinical Symptoms in Patients with Parkinson’s Disease
文章编号:
1671-7414（2022）03-182-06
作者:
闫　欣1; 商素亮2; 李　娜1; 武　娇1
（1. 保定市第二中心医院神经内科，河北保定 072750; 2. 河北省第八人民医院老年科，石家庄 050000）
Author(s):
YAN Xin1;  SHANG Su-liang2;  LI Na1;  WU Jiao1
(1. Department of Neurology, the Second Central Hospital of Baoding City, Hebei Baoding 072750,China； 2. Department of Geriatrics, the Eighth People’s Hospital of Hebei Province, Shijiazhuang 050000, China)
关键词:
帕金森病; 鞘氨醇1 磷酸; 高密度脂蛋白胆固醇
分类号:
R742.5；R392.11
DOI:
10.3969/j.issn.1671-7414.2022.03.038
文献标志码:
A
摘要:
目的　分析帕金森病（ Parkinson’s disease，PD）患者血浆鞘氨醇 1磷酸（ sphingosine 1 phosphate，S1P）、高密度脂蛋白胆固醇（ high density lipoprotein cholesterol，HDL-C）表达水平，探讨二者与 PD患者临床症状的关系。方法　选择 2018年 7月～ 2021年 3月于保定市第二中心医院确诊的 PD患者 100例作为研究对象（ PD组），根据 HoehnYahr分期将患者分为轻度组（ 1～ 2期）35例、中度组（ 2.5～ 3期）36例和重度组（ 4～ 5期）29例。另选取同期健康体检者 105例为对照组。测定血浆 S1P和 HDL-C表达水平；比较不同严重程度 PD患者运动症状及非运动症状评分；采用 Pearson法分析 PD患者血浆 S1P和 HDL-C表达水平与运动症状评分和非运动症状评分相关性； Logistic回归分析影响重度 PD的危险因素。结果　PD组患者血浆 S1P（298.77±142.22 pmol/ml ）和 HDL-C（0.96±0.24 mmol/L）表达水平显著低于对照组（ 512.66±201.31 pmol/ml，1.87±0.33mmol/L），差异有统计学意义（ t=8.744，20.327，均 P =0.000）。轻度、中度和重度组血浆 S1P（395.33±156.66 pmol/ml，290.73±142.60 pmol/ml，210.25±113.07 pmol/ ml）与 HDL-C（1.36±0.29 mmol/L，1.07±0.25 mmol/L，0.45±0.16 mmol/L）表达水平依次降低，差异有统计学意义（F=14.090，113.414，均 P =0.000）。轻度组、中度组和重度组统一帕金森病评定量表第Ⅲ部分（ uni.ed parkinson’s disease rating scale Ⅲ ,UPDRS Ⅲ）评分（ 26.89±8.63分，43.11±16.66分，56.79±27.27分）、汉密尔顿抑郁量表（Hamilton depression scale ，HAMD）评分（ 12.35±3.96分，19.63±4.87分，25.18±5.17分）与汉密尔顿焦虑量表（Hamilton anxiety scale,HAMA）评分（ 8.86±2.67分，16.93±3.89分，26.79±5.83分）依次升高，差异均有统计学意义（ F=20.648， 61.097，146.366，均 P=0.000）。简易精神状态检查（ mini-mental state examination ，MMSE）评分（ 23.67±4.37分， 16.58±3.67分，12.06±2.15分）依次降低，差异有统计学意义（ F=85.925，P=0.000）。PD组患者血浆 S1P表达水平与 HDL-C表达水平呈正相关（ r=0.633，P=0.007），二者与 UPDRS Ⅲ评分、 HAMD评分和 HAMA评分均呈负相关（r=-0.605～ -0.480，均 P＜ 0.05），与 MMSE评分呈正相关（ r=0.587，0.518，均 P＜ 0.05）。血浆 S1P，HDL-C表达水平降低是影响重度 PD的独立危险因素 [OR（95%CI）为 1.936（1.265～ 2.962）和 2.011（1.372～ 2.947）]（均 P＜ 0.05）。结论　血浆 S1P和 HDL-C异常低表达可能与 PD患者临床症状有关。临床可以通过监测血浆 S1P和 HDL-C表达水平，评估 PD发生、严重程度及临床症状的变化，可作为 PD的辅助诊断手段。
Abstract:
Objective　To analyze the plasma levels of sphingosine1phosphate (S1P) and high density lipoprotein cholesterol (HDL-C) in patients with Parkinson’s disease (PD), and explore the relationship between them and clinical symptoms of PD. Methods　100 PD patients diagnosed in the Second Central Hospital of Baoding City from July 2018 to March 2021 were selected as the research objects (PD group). According to HoehnYahr stage, the patients were divided into mild group (stage 1 ～ 2) 35 cases, moderate group (stage 2.5 ～ 3) 36 cases and severe group (stage 4 ～ 5) 29 cases. Another 105 healthy people were selected as control group，and plasma levels of S1P and HDL-C were measured. The scores of motor symptoms and non motor symptoms of PD patients with different severity were compared.Pearson method was used to analyze the correlation between plasma S1P, HDL-C levels and motor symptom score, non motor symptom score in PD patients,and Logistic regression analysis was used to analyze the risk factors of severe PD. Results　The plasma S1P (298.77±142.22 pmol/ml), HDL- C (0.96±0.24 mmol/L) expression level in PD group was significantly lower than that in the control group （512.66±201.31 pmol/ml，1.87±0.33mmol/L），the differences were statistically significant (t=8.744，20.327, all P=0.000). The expression levels of plasma S1P (395.33±156.66 pmol/ml, 290.73±142.60 pmol/ml，210.25±113.07 pmol/ml) and HDL-C (1.36±0.29 mmol/L, 1.07±0.25 mmol/L, 0.45±0.16 mmol/L) in mild, moderate and severe groups decreased in turn ，the differences were statistically significant (F=14.090, 113.414, all P=0.000). In mild, moderate and severe groups, the scores of Unified Parkinson’s disease rating scale Part III (UPDRS Ⅲ ) score (26.89±8.63 score, 43.11±16.66 score ，56.79±27.27 score), hamilton depression scale (HAMD) score (12.35±3.96 score, 19.63±4.87 score，25.18±5.17 score), hamilton anxiety scale (HAMA) score (8.86±2.67 score, 16.93±3.89 score，26.79±5.83 score) increased in turn， the differences were statistically significant (F=20.648, 61.097, 146.366, all P=0.000), the minimental state examination (MMSE) score (23.67±4.37 score，16.58±3.67 score，12.06±2.15 score) was decreased in sequence，the difference was statistically significant (F=85.925, P=0.000). In PD group, plasma S1P expression level was positively correlated with HDL-C expression level (r=0.633, P=0.007), and they were negatively correlated with UPDRS Ⅲ score, HAMD score and HAMA score (r=-0.605 ～ -0.480, all P ＜ 0.05), and positively correlated with MMSE score (r =0.587, 0.518, all P ＜ 0.05). The decreased expression levels of plasma S1P and HDL-C were independent risk factors for severe PD [OR (95% CI) was 1.936 (1.265 ～ 2.962) and 2.011 (1.372 ～ 2.947)] (all P ＜ 0.05). Conclusion　The abnormal low expressions of plasma S1P and HDL-C may be related to the clinical symptoms of PD patients. The occurrence, severity of PD and the changes of clinical symptoms can be evaluated by monitoring the plasma levels of S1P and HDL-C, it can be used as an auxiliary diagnostic means of PD.

参考文献/References:

[1] YOO H S, CHUNG S J, LEE Y H, et al. Cognitive anosognosia is associated with frontal dysfunction and lower depression in Parkinson’s disease[J]. European Journal of Neurology, 2020, 27(6): 951-958.
[2] PANG Marco Y C. Physiotherapy management of Parkinson’s disease[J]. Journal of Physiotherapy, 2021, 67(3): 163-176.
[3] ANIS E, ZAFEER M F, FIRDAUS F, et al. Perillyl alcohol mitigates behavioural changes and limits cell death and mitochondrial changes in unilateral 6-OHDA lesion model of Parkinson’s disease through alleviation of oxidative stress[J]. Neurotoxicity Research, 2020, 38(2): 461-477.
[4] QIANG Guanghui, WANG Zhongxia, JI Ailai, et al. Sphingosine kinase 1 knockout alleviates hepatic ischemia/reperfusion injury by attenuating inflammation and oxidative stress in mice[J]. Hepatobiliary & Pancreatic Diseases International: 2019, 18(3): 255- 265.
[5] WANG Xiaopu, PEI Junyu, ZHENG Keyang, et al. Highdensity lipoprotein cholesterol levels are associated with major adverse cardiovascular events in male but not female patients with hypertension[J]. Clinical Cardiology, 2021, 44(5): 723-730.
[6] 王守章，刘红军．老年帕金森病患者血脂、同型 半胱氨酸和尿酸水平的变化[J]. 中国老年学杂志, 2017, 37(19):4778-4779. WANG Shouzhang, LIU Hongjun. Changes of blood lipid, homocysteine and uric acid levels in elderly patients with Parkinson’s disease[J]. Chinese Journal of Gerontology, 2017, 37(19):4778-4779.
[7] GUPTA D K, FAHN S, TATSUOKA C, et al. Hoehn and Yahr stage 3 and postural stability item in the movement disorder societyunified Parkinson’s disease rating scale[J]. Movement Disorders, 2018, 33(7): 1188-1189.
[8] 中华医学会神经病学分会帕金森病及运动障碍学 组，中国医师协会神经内科医师分会帕金森病及运 动障碍专业．中国帕金森病的诊断标准(2016 版)[J]. 中华神经科杂志, 2016, 49(4):268-271. Chinese Medical Association Neurology Branch of Parkinson’s Disease and Movement Disorders Group, Chinese Physician Association Neurologist Branch of Parkinson s Disease and Movement Disorders Professional Committe. Diagnostic criteria for Parkinson’s disease in China (2016 Edition)[J]. Chinese Journal of Neurology, 2016, 49(4):268-271.
[9] DRIVER-DUNCKLEY E D, ZHANG Nan, SHILL H A, et al. Correlation between the movement disorder society’s unified Parkinson’s disease rating scale and nonmotor scales in patients with parkinson’s disease[J]. Innovations in Clinical Neuroscience, 2019, 16(9/10): 27-29.
[10] NEDA F, AKRAM K. MMSE and maximum a posteriori estimators for speech enhancement in additive noise assuming a t-location-scale clean speech prior[J]. IET Signal Processing, 2018, 12(4): 532-543.
[11] GALE C, GLUE P, GUAIANA G, et al. Influence of covariates on heterogeneity in Hamilton Anxiety Scale ratings in placebo-controlled trials of benzodiazepines in generalized anxiety disorder: Systematic review and metaanalysis[J]. Journal of Psychopharmacology (Oxford, England), 2019, 33(5): 543-547.
[12] VINDBJERG E, MAKRANSKY G, MORTENSEN E L, et al. Cross-cultural psychometric properties of the Hamilton depression rating scale[J]. Canadian Journal of Psychiatry Revue Canadienne de Psychiatrie, 2019, 64(1): 39-46.
[13] DEUTSCHLANDER A B, KONNO T, SOTOBEASLEY A, et al. Association of MAPT subhaplotypes with clinical and demographic features in Parkinson’s disease[ J]. Annals of Clinical and Translational Neurology, 2020, 7(9): 1557-1563.
[14] 钟瑞霞，秦雅静，陈忠彦，等. 帕金森病发病机 制及其早期诊断的研究进展[J]. 中国综合临床， 2019，35(3):276-280. ZHONG Ruixia, QIN Yajing, CHEN Zhongyan, et al. Progress in pathogenesis and early diagnosis of Parkinson’s disease [J]. Clinical Medicine of China, 2019, 35(3):276-280.
[15] KARUPPUCHAMY T, TYLER C J, LUNDBORG L R, et al. Sphingosine1 phosphate lyase inhibition alters the S1P gradient and ameliorates crohn’s like ileitis by suppressing thymocyte maturation[J]. Inflammatory Bowel Diseases, 2020, 26(2): 216-228.
[16] 张灵玲，熊大迁，葛一漫，等. 血清载脂蛋白M 与 1 磷酸鞘氨醇在细菌性血流感染中的表达及相关性 研究[J]. 现代检验医学杂志,2019, 34(5):56-58, 63. ZHANG Lingling, XIONG Daqian, GE Yiman, et al. Expression and correlation of serum apolipoprotein M and sphingosine 1-phosphate in bacterial bloodstream infection [J]. Journal of Modern Laboratory Medicine,2019, 34(5):56-58，63.
[17] ESAKI K, BALAN S, IWAYAMA Y, et al. Evidence for altered metabolism of sphingosine1 phosphate in the corpus callosum of patients with schizophrenia[J]. Schizophrenia Bulletin, 2020, 46(5): 1172-1181.
[18] DIRR E, EKHATOR O R, BLACKWOOD R, et al. Exacerbation of sensorimotor dysfunction in mice deficient in Atp13a2 and overexpressing human wildtype alphasynuclein[J]. Behavioural Brain Research, 2018, 343(1): 41-49.
[19] 李智，高燕．单核细胞/ 高密度脂蛋白胆固醇值与 冠心病关系研究进展[J]．临床误诊误治，2019，32 （2）：103-106． LI Zhi, GAO Yan. Research progress on the relationship between monocyte / high density lipoprotein cholesterol and coronary heart disease[J]. Clinical Misdiagnosis & Mistherapy, 2019, 32(2):103-106.
[20] YANG Wanlin, CHANG Zihan, QUE Rongfang, et al. Contra directional expression of plasma superoxide dismutase with lipoprotein cholesterol and high sensitivity creactive protein as important markers of Parkinson’s disease severity[J]. Frontiers in Aging Neuroscience, 2020, 12(1): 53.
[21] WAMELEN D J, TADDEI R N, CALVANO A, et al. Serum uric acid levels and non-motor symptoms in Parkinson’s disease[J]. Journal of Parkinson’s Disease, 2020, 10(3): 1003-1010.
[22] SI Xu, LI Yibo, JIANG Yugang, et al. γ-Aminobutyric acid attenuates high-fat diet-induced cerebral oxidative impairment via enhanced synthesis of hippocampal sulfatides[J]. Journal of Agricultural and Food Chemistry, 2019, 67(4): 1081-1091.
[23] 张照婷，陈皆春，华平，等.α 突触核蛋白基因多 态性与汉族帕金森病患者病情进展的相关性研究 [J]. 中国临床神经科学, 2020, 28(1):21-26. ZHANG Zhaoting, CHEN Jiechun, HUA Ping, et al. Association between SNCA gene polymorphism and Parkinson’s disease in Han population [J]. Chinese Journal of Clinical Neurosciences , 2020, 28(1):21-26.
[24] 刘茹，张素芬，李红军，等. 帕金森病患者认知功 能障碍的危险因素分析[J]. 河北医科大学学报， 2019，40(10):1211-1213. LIU Ru, ZHANG Sufen, LI Hongjun, et al. Analysis of risk factors of cognitive dysfunction in patients with Parkinson’s disease[J]. Journal of Hebei Medical University, 2019, 40(10):1211-1213.

相似文献/References:

[1]武 琪a,陈 亮b,张宝华c.帕金森病患者血清和脑脊液褪黑素水平变化及其临床意义[J].现代检验医学杂志,2017,32(05):90.[doi:10.3969/j.issn.1671-7414.2017.05.017]
　WU Qia,CHEN Liangb,ZHANG Bao-huac.Changes and Clinical Significance of Melatonin in Blood and Cerebrospinal Fluid of Patients with Parkinson's Disease[J].Journal of Modern Laboratory Medicine,2017,32(03):90.[doi:10.3969/j.issn.1671-7414.2017.05.017]
[2]武 琪a,张宝华b.Nrf2基因启动子-653G/A,-651G/A和-617C/A位点单核苷酸多态性与帕金森病易感性的关联性研究[J].现代检验医学杂志,2017,32(06):60.[doi:10.3969/j.issn.1671-7414.2017.06.001]
　WU Qia,ZHANG Bao-huab.Association between Nrf2 Gene -653G/A,-651G/A and -617C/A Polymorphism and Susceptibility of Parkinson's Disease[J].Journal of Modern Laboratory Medicine,2017,32(03):60.[doi:10.3969/j.issn.1671-7414.2017.06.001]
[3]李泽东,詹　贞,刘　忆,等.帕金森病患者血清鳞状细胞癌抗原（SCC-Ag）表达的临床意义[J].现代检验医学杂志,2019,34(06):70.[doi:10.3969 ／ j.issn.1671-7414.2019.06.017]
　LI Ze-dong,ZHAN Zhen,LIU Yi,et al.Significance of SCC Antigen Expression in Parkinson’s Disease[J].Journal of Modern Laboratory Medicine,2019,34(03):70.[doi:10.3969 ／ j.issn.1671-7414.2019.06.017]
[4]尚天明,毕开湘.唾液 α- 突触核蛋白 (SNCA) 与嗅觉评估在帕金森病早期筛查中的应用研究[J].现代检验医学杂志,2020,35(06):95.[doi:doi:10.3969/j.issn.1671-7414.2020.06.023]
　SHANG Tian-ming,BI Kai-xiang.Application Research of Olfactory Assessment and Salivary SNCA in EarlyScreening of Parkinson’s Disease[J].Journal of Modern Laboratory Medicine,2020,35(03):95.[doi:doi:10.3969/j.issn.1671-7414.2020.06.023]
[5]李群英,甄时建,何树光,等.帕金森病患者治疗期间血清miR-153，miR-128b水平表达与非运动症状的相关性研究[J].现代检验医学杂志,2021,36(05):120.[doi:10.3969/j.issn.1671-7414.2021.05.027]
　LI Qun-ying,ZHEN Shi-jian,HE Shu-guang,et al.Research on Correlation between Expression of Serum miR-153, miR-128bLevels and Non-motor Symptoms in Patients with Parkinson’s DiseaseDuring Treatment Period[J].Journal of Modern Laboratory Medicine,2021,36(03):120.[doi:10.3969/j.issn.1671-7414.2021.05.027]
[6]白 雪,董巧云,赵 丽,等.帕金森病患者血清miR-7 和α-Syn 表达水平与认知功能障碍的相关性研究[J].现代检验医学杂志,2023,38(04):78.[doi:10.3969/j.issn.1671-7414.2023.04.014]
　BAI Xue,DONG Qiaoyun,ZHAO Li,et al.Correlation between Serum miR-7 and α-Syn Expression Levels and Cognitive Impairment in Patients with Parkinson’s Disease[J].Journal of Modern Laboratory Medicine,2023,38(03):78.[doi:10.3969/j.issn.1671-7414.2023.04.014]
[7]郑德泉,江 华,林锦标,等.帕金森病患者血清NPASDP-4，MBP 水平表达与认知功能障碍及严重程度的诊断价值研究[J].现代检验医学杂志,2024,39(03):17.[doi:10.3969/j.issn.1671-7414.2024.03.003]
　ZHENG Dequan,JIANG Hua,LIN Jinbiao,et al.Study on the Diagnostic Value of Serum NPASDP-4 and MBP Level Expression with Cognitive Dysfunction and Severity in Parkinson’s Disease Patients[J].Journal of Modern Laboratory Medicine,2024,39(03):17.[doi:10.3969/j.issn.1671-7414.2024.03.003]
[8]牛荣荣,宋世雄,宋 蕾.帕金森病患者血清FGF22 和CXCL16 水平检测对认知障碍的诊断价值[J].现代检验医学杂志,2024,39(03):152.[doi:10.3969/j.issn.1671-7414.2024.03.026]
　NIU Rongrong,SONG Shixiong,SONG Lei.Diagnostic Value of Serum FGF22 and CXCL16 Levels in Patients with Parkinson’s Disease for Cognitive Impairment[J].Journal of Modern Laboratory Medicine,2024,39(03):152.[doi:10.3969/j.issn.1671-7414.2024.03.026]
[9]曹明月,王 巍,周美宁.LPIN1/PPARA 通过抑制SLC47A1 介导的神经元铁死亡缓解帕金森病模型大鼠病情进展的机制研究[J].现代检验医学杂志,2024,39(04):63.[doi:10.3969/j.issn.1671-7414.2024.04.012]
　CAO Mingyue,WANG Wei,ZHOU Meining.Mechanism Study on LPIN1/PPARA Alleviating the Progression of Parkinson’s Disease in Rats by Inhibiting SLC47A1-Mediated Ferroptosis of Neurons[J].Journal of Modern Laboratory Medicine,2024,39(03):63.[doi:10.3969/j.issn.1671-7414.2024.04.012]

备注/Memo

备注/Memo:
基金项目：河北省医学科学研究课题计划项目（编号20200267）。
作者简介：闫欣（1986-），女，硕士，主治医师，研究方向：帕金森病的临床研究，E-mail:yanxinxin685@163.com。
通讯作者：商素亮（1976-），男，硕士，副主任医师，研究方向：帕金森病的临床诊疗，E-mail:pumchfwh@sina.com。
更新日期/Last Update: 1900-01-01